Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Clinical drug investigation - 1 Oct 2018

Metro Giulio, Baglivo Sara, Siggillino Annamaria, Ludovini Vienna, Chiari Rita, Rebonato Alberto, Bellezza Guido

Abstract excerpt

Osimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. On the other hand, there is a lack of therapeutic strategies with proven efficacy at the time of progression on osimertinib. If not administered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Piperazines

Share to Treatment Outcome

Source

Identifiers

PMID: 30151614
DOI: 10.1007/s40261-018-0691-8

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.PMID 30151614Read ↗

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.Semantic proximity Read ↗

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.Semantic proximity Read ↗

Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.Semantic proximity Read ↗

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non-Small-Cell Lung Cancer After Progression on Erlotinib.Semantic proximity Read ↗

Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.Semantic proximity Read ↗

Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.Semantic proximity Read ↗

Re-use of erlotinib in a patient using osimertinib after erlotinib, case report.Semantic proximity Read ↗

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.Semantic proximity Read ↗

Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer.Semantic proximity Read ↗

Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.